Pediatric Pharmacology and Spasticity Management

Section 1: Pediatric Pharmacokinetics and the Spasticity Ladder

~0:00 – Pediatric Pharmacokinetics and the Spasticity…

Bottom line: pediatric drug dosing is weight-based because clearance scales with size, but pharmacokinetic parameters change non-linearly with maturation; the spasticity management ladder progresses through six steps from physical management to orthopedic surgery, and the oral antispasticity rung is dominated by four agents (baclofen, dantrolene, tizanidine, diazepam) of which only diazepam carries a Level B American Academy of Neurology recommendation.

Pediatric pharmacology is not adult pharmacology with smaller numbers. Children differ from adults across every pharmacokinetic compartment. Total body water is approximately 75-80% in neonates and falls toward the adult value of 60% during the first year. This expanded volume of distribution dilutes hydrophilic drugs and changes the loading dose of weight-based regimens. Albumin and alpha-1-acid glycoprotein binding capacity is reduced in neonates, raising the free fraction of highly bound drugs such as phenytoin and lorazepam. Hepatic cytochrome P450 (CYP450) enzymes mature on different timetables: CYP3A4 reaches adult activity by approximately 12 months, while CYP2D6 follows a slower trajectory, producing variable metabolism of substrates such as codeine and dextromethorphan during the first years. Glomerular filtration rate (GFR) at term is approximately 30-40% of adult values and reaches adult levels (corrected for body surface area) by 6-12 months, governing clearance of renally eliminated drugs such as gentamicin and vancomycin. The clinical consequence is that dosing intervals and absolute doses shift with age, and weight-based dosing must be coupled with developmental knowledge.

The spasticity management ladder, endorsed by the American Academy of Neurology (AAN), the National Institute for Health and Care Excellence (NICE), and the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM), provides the framework for matching intervention intensity to spasticity severity and distribution. Step 1 is physical management with stretching, positioning, serial casting, and orthotics. Step 2 is oral antispasticity medication. Step 3 is focal chemodenervation with botulinum toxin or phenol. Step 4 is intrathecal baclofen for severe generalized spasticity. Step 5 is selective dorsal rhizotomy for the carefully selected ambulatory diplegic child. Step 6 is orthopedic surgery for fixed contracture or bony deformity. The ladder is not strictly sequential. Many children receive interventions from multiple rungs simultaneously; oral baclofen for generalized tone may coexist with botulinum toxin for focal equinus and a physical therapy program throughout.

The four oral antispasticity agents are baclofen, dantrolene, tizanidine, and diazepam, and the AAN evidence levels matter on the boards. Baclofen is a gamma-aminobutyric acid type B (GABA-B) receptor agonist that exerts presynaptic inhibition in the spinal cord, reducing release of excitatory amino acids onto motor neurons. Pediatric dosing starts at 0.5 mg/kg/day divided two to three times daily, titrated weekly to a target range of 1-2 mg/kg/day, with a maximum of approximately 60 mg/day in children and 80 mg/day in adolescents. Oral baclofen has poor central nervous system (CNS) penetration with only about 5% of an oral dose crossing the blood-brain barrier, which is why intrathecal delivery achieves equivalent effect at 100- to 1,000-fold lower doses. AAN level: U (insufficient evidence per Delgado 2010). The most dangerous adverse event is abrupt withdrawal, which can precipitate seizures, hallucinations, and rebound spasticity; baclofen must always be tapered. Dantrolene is the only peripherally acting antispasticity agent. It binds the ryanodine receptor (RyR1) in skeletal muscle, blocking calcium release from the sarcoplasmic reticulum and reducing excitation-contraction coupling. Pediatric dosing begins at 0.5 mg/kg once daily and titrates to a maximum of 2 mg/kg four times daily. Idiosyncratic hepatotoxicity is the defining adverse effect, with case-fatality rates as high as 28% reported in the literature. Liver function tests are checked at baseline and monthly for the first six months. AAN level: U (insufficient evidence per Delgado 2010). Tizanidine is a centrally acting alpha-2 adrenergic agonist that enhances presynaptic inhibition in the spinal cord. Dosing is started at 1-2 mg at bedtime and titrated by 2-4 mg every three to seven days. It is metabolized by CYP1A2 and is contraindicated with potent CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin, which can produce profound hypotension and sedation. AAN level: C (possibly effective per Delgado 2010, reaffirmed July 2025 — “may be considered”). Diazepam enhances GABA-A receptor function at spinal and supraspinal levels. Pediatric dosing is 0.1-0.3 mg/kg/day divided two to four times daily. Diazepam carries the strongest pediatric AAN evidence among oral antispasticity agents (Level B in the 2010 Delgado AAN Practice Parameter — “probably effective”) in pediatric cerebral palsy, but its side-effect profile (sedation, tolerance, dependence, respiratory depression) limits long-term use. Like baclofen, diazepam must be tapered to avoid withdrawal seizures.